Following NHS England’s updated guidance on the use of flash blood glucose testing systems for patients the CCG has reviewed the commissioning criteria and amended the existing criteria. New criteria are below in bold:
- People with Type 1 diabetes who need intensive monitoring (more than 8 times every day) as demonstrated in a review over the past 3 months
- People with Type 1 diabetes associated with cystic fibrosis on insulin treatment
- Pregnant women with Type 1 Diabetes – 12 months in total inclusive of post-delivery period
- Type 1 diabetics who meet the current NICE criteria for insulin pump therapy (HbA1c >8.5% (69.4mmol/mol) or disabling hypoglycemia as described in NICE TA151) where a successful trial of FreeStyle Libre® may avoid the need for pump therapy.
- Type 1 diabetics who have recently developed impaired awareness of hypoglycaemia. It is noted that for persistent hypoglycaemia unawareness, NICE recommend continuous glucose monitoring with alarms and Freestyle Libre does currently not have that function.
- Type 1 diabetics with frequent admissions (>2 per year) with DKA or hypoglycaemia.
- Type 1 diabetics who require third parties to carry out monitoring and where conventional blood testing is not possible.
- Children who have significant fear or anxieties of multiple finger prick testing. [This is any child / young person who is diagnosed when less than 16 years of age. These children/young people should fulfill continuation criteria to continue with FGS]
- People with Type 1 diabetes for whom the specialist diabetes MDT determines have occupational circumstances that warrant a 6-month trial of Libre with appropriate support.
- Adults (16 or over) with Type 1 diabetes for whom the specialist diabetes MDT determines have psychosocial circumstances that warrant a 6-month trial of Libre with appropriate support. An IFR request should be made by the specialist team.
Prescriptions will be initiated by specialist teams and prescribing continued by GP practice after the first month.